GlassScriptPhysician profile
Achuta K Guddati
NPI 1457639312
$2,551.93
in general payments reported to CMS, 2019-2025
9 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,000 · 2021: $15.54 · 2022: $148 · 2024: $525 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,175 · Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,175.00 |
| Food and Beverage | $213.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,175.00 | 2024-2025 | Vanflyta, Enhertu |
| Merck Sharp & Dohme LLC | $1,006.49 | 2020-2022 | |
| Caris Mpi, INC. | $131.52 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.33 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $27.71 | 2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $21.17 | 2025 | |
| Epizyme, INC. | $16.17 | 2020 | |
| Novo Nordisk INC | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Achuta Guddati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.